Read + Share
Zhao S, Ma Y, Liu L, Fang J, et al. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and
AXL dysregulations: A phase 1b clinical trial and biomarker analysis. Lung Cancer 2024;188:107468.
PMID: 38181454
|
 |
|
Zhao S, Ma Y, Liu L, Fang J, et al. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and
AXL dysregulations: A phase 1b clinical trial and biomarker analysis. Lung Cancer 2024;188:107468.
PMID: 38181454
|
|
|
|